132 related articles for article (PubMed ID: 22374530)
21. Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma.
Chang ET; Zheng T; Lennette ET; Weir EG; Borowitz M; Mann RB; Spiegelman D; Mueller NE
J Infect Dis; 2004 Jun; 189(12):2271-81. PubMed ID: 15181575
[TBL] [Abstract][Full Text] [Related]
22. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
Lin JC; Wang WY; Chen KY; Wei YH; Liang WM; Jan JS; Jiang RS
N Engl J Med; 2004 Jun; 350(24):2461-70. PubMed ID: 15190138
[TBL] [Abstract][Full Text] [Related]
23. EBV DNA: a Hodgkin lymphoma biomarker?
Meyer RM
Blood; 2013 May; 121(18):3541-2. PubMed ID: 23640993
[TBL] [Abstract][Full Text] [Related]
24. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
Skugor ND; Perić Z; Vrhovac R; Radić-Kristo D; Kardum-Skelin I; Jaksić B
Coll Antropol; 2010 Mar; 34(1):241-5. PubMed ID: 20432757
[TBL] [Abstract][Full Text] [Related]
25. Natural killer cell-type body cavity lymphoma following chronic active Epstein-Barr virus infection.
Ogata M; Imamura T; Mizunoe S; Ohtsuka E; Kikuchi H; Nasu M
Am J Hematol; 2003 Jun; 73(2):126-30. PubMed ID: 12749015
[TBL] [Abstract][Full Text] [Related]
26. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
Barkholt L; Linde A; Falk KI
Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
[TBL] [Abstract][Full Text] [Related]
27. Cell-free epstein-barr viral loads in childhood hodgkin lymphoma: a study from South India.
Sinha M; Rao CR; Shafiulla M; Appaji L; Bs AK; Sumati BG; Avinash T; Jayshree RS
Pediatr Hematol Oncol; 2013 Sep; 30(6):537-43. PubMed ID: 23756088
[TBL] [Abstract][Full Text] [Related]
28. [Adoptive transfer of Epstein-Barr virus-specific T-lymphocytes in chronic active Epstein-Barr infection].
Babel N; Hammer MH; Reinke P
Dtsch Med Wochenschr; 2003 Mar; 128(11):548-50. PubMed ID: 12635027
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of Epstein-Barr virus DNA levels in serum during EBV-associated disease.
Berger C; Day P; Meier G; Zingg W; Bossart W; Nadal D
J Med Virol; 2001 Aug; 64(4):505-12. PubMed ID: 11468736
[TBL] [Abstract][Full Text] [Related]
30. Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.
Suzuki T; Takeuchi M; Saeki H; Yamazaki S; Koga H; Abe D; Nishimura M; Nakaseko C; Nakasa H; Nakamura H; Ariyoshi N; Kitada M
Clin Ther; 2010 Mar; 32(3):527-31. PubMed ID: 20399989
[TBL] [Abstract][Full Text] [Related]
31. Can we use EBV-DNA monitoring to predict disease relapse in EBV-positive hodgkin lymphoma patients?
Spacek M; Hubacek P; Markova J; Zajac M; Vernerova Z; Kozak T
Acta Haematol; 2010; 124(1):23-6. PubMed ID: 20606412
[No Abstract] [Full Text] [Related]
32. Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma.
Fafi-Kremer S; Brengel-Pesce K; Barguès G; Bourgeat MJ; Genoulaz O; Seigneurin JM; Morand P
J Clin Virol; 2004 Jun; 30(2):157-64. PubMed ID: 15125872
[TBL] [Abstract][Full Text] [Related]
33. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma.
Van Baarle D; Wolthers KC; Hovenkamp E; Niesters HG; Osterhaus AD; Miedema F; Van Oers MH
J Infect Dis; 2002 Aug; 186(3):405-9. PubMed ID: 12134237
[TBL] [Abstract][Full Text] [Related]
34. Minimal-change nephrotic syndrome preceding Hodgkin lymphoma by 5 years with expression of tumor necrosis factor alpha in Hodgkin-Reed-Sternberg cells.
Nakayama S; Yokote T; Kobayashi K; Hirata Y; Akioka T; Hiraoka N; Oka S; Miyoshi T; Takubo T; Tsuji M; Hanafusa T
Hum Pathol; 2010 Aug; 41(8):1196-9. PubMed ID: 20624522
[TBL] [Abstract][Full Text] [Related]
35. EBV Plasma Epstein-Barr Virus (EBV) DNA as a Biomarker for Diagnosis of EBV-positive Hodgkin Lymphoma in Syria.
Habeeb R; Al Hafar L; Monem F
J Infect Dev Ctries; 2021 Dec; 15(12):1917-1922. PubMed ID: 35044951
[TBL] [Abstract][Full Text] [Related]
36. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
37. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
38. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
39. Quantitative PCR in EBV-infected renal transplant patients.
Merlino C; Cavallo R; Bergallo M; Giorgi S; Forgnone F; Re D; Sinesi F; Musso T; Negro Ponzi A
New Microbiol; 2001 Jul; 24(3):223-9. PubMed ID: 11497078
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Role of the Expression of Latent-Membrane Protein 1 of Epstein-Barr Virus in Classical Hodgkin Lymphoma.
Santisteban-Espejo A; Perez-Requena J; Atienza-Cuevas L; Moran-Sanchez J; Fernandez-Valle MDC; Bernal-Florindo I; Romero-Garcia R; Garcia-Rojo M
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
